ZURA250117C2500
- 0.05
- 0.000.00%
Zura Bio Newsroom
Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
H.C. Wainwright Maintains Zura Bio(ZURA.US) With Hold Rating, Maintains Target Price $5
Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks
HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target
Zura Bio Analyst Ratings
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $12
Zura Bio (ZURA) Receives a Buy From Piper Sandler
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
H.C. Wainwright Maintains Zura Bio(ZURA.US) With Hold Rating, Maintains Target Price $5
Zura Bio Analyst Ratings
H.C. Wainwright Maintains Zura Bio(ZURA.US) With Hold Rating, Maintains Target Price $5
Cautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial Uncertainty
Chardan Capital Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $15
Zura Bio Price Target Cut to $12.00/Share From $14.00 by Chardan Capital
Zura Bio Is Maintained at Buy by Chardan Capital
Zura Bio Analyst Ratings
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $26
Leerink Partners Initiates Zura Bio(ZURA.US) With Buy Rating, Announces Target Price $15